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ABSTRACT  
Hyperactivation of the Mitogen Activated Protein Kinase (MAPK) pathway is prevalent in melanoma, 
principally due to mutations in the B-Raf and NRas genes. MAPK inhibitors are effective only short-
term, and recurrence occurs due to functional redundancies or intertwined pathways. The 
remodeling of Ca2+ signaling is also common in melanoma cells, partly through the increased 
expression of T-type channels (TTCCs). Here we summarize current knowledge about the prognostic 
value and molecular targeting of TTCCs. Furthermore, we discuss recent evidence pointing to TTCCs 
as molecular switches for melanoma chemoresistance, which set the grounds for novel combined 
therapies against the advanced disease.  
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Introduction 
The mitogen-activated protein kinase (MAPK) pathway plays a pivotal role in cancer progression by 
supporting cell proliferation, survival and migration [1]. Constitutive activation of the MAPK pathway 
occurs in up to 80-90% of cutaneous melanomas, mostly due to gain-of-function mutations in the B-
Raf (>50%) and NRas (20-30%) genes. These cells are highly dependent on MAPK signaling and thus 
particularly vulnerable to MAPK inhibitors. Direct inhibition of Ras GTPases has proved unsuccessful 
so far, and efforts have concentrated on downstream effectors instead. However, available MAPK 
inhibitors targeting serine-threonine kinases BRAF or MEK, although often effective in the short-term, 
eventually trigger the activation of adaptive pathways that confer resistance to the treatment. One 
such pathway is the phosphoinositide 3-kinase (PI3K)-Akt, which can be activated by RAS and by 
mutations leading to the loss-of-function of phosphatase and tensin homologue (PTEN) [2], often 
concurrent with BRAF mutations [3]. Correspondingly, combined therapies co-targeting different 
components of the MAPK pathway and other survival routes are subject to intense research in order 
to increase treatment efficacy [4].  
G1-S phase transition is dependent on Ca2+ influx through channels present in the plasma membrane, 
and subsequent activation of central Ca2+ regulator calmodulin (CaM). From there, Ca2+-CaM 
facilitates cell cycle progression by binding to different cyclins/cyclin dependent kinases and by 
activating a plethora of kinases and/or phosphatases, in a context-dependent manner [5]. Among the 
many channels involved, voltage-gated T-type Ca2+ channels (TTCCs) play a cryptic, yet pivotal role in 
G1-S transition by virtue of their unique biophysical properties, which can be summarized in 
activation at low voltages, rapid inactivation and slow deactivation kinetics [6]. 
TTCCs are expressed in cancer cells and have become appealing candidates for chemotherapeutic 
targeting as they regulate different signaling pathways and cellular mechanisms favoring cancer cell 
proliferation, survival and invasiveness [7]. Because of these multilevel actions, pharmacological 
block of TTCCs offers the possibility to inhibit a core pathway for cancer cells thriving, as well as 
putative escape routes for treatment resistance. Indeed, recent research has set the grounds for 
complementary targeting of TTCCs and components of the MAPK pathway. 
 
Prognostic value of T-type Ca2+ channels expression in melanoma 
A pan-cancer view of TTCCs shows that their three isoforms (Cav3.1, Cav3.2 and Cav3.3) are expressed 
at variable levels according to cancer types and stages, including over- and under-expression when 
compared to normal tissues [7][8]. Transcriptional regulation of TTCCs is largely unknown, beyond 
the induction of Cav3.2 channels by hypoxia-inducible factors (HIFs) [9][10][11]. Of note, Cacna1g 
(encoding Cav3.1 channels) has been deemed as a tumor suppressor gene because of its aberrant 
methylation in 18-35% of different human primary tumors [12][13][14]. Nonetheless, the expression 
of transcripts for all TTCCs isoforms is increased in melanoma cells compared to melanocytes or nevus 
cells [7].  
We performed seminal research back in 2012, when we showed that cultured melanoma cells 
express functional voltage-gated Ca2+ channels in their plasma membrane, including TTCCs which are 
barely detectable in untransformed melanocytes [15]. Of the three existing TTCCs isoforms, we also 
identified Cav3.1 as the prevalent one in highly autophagic cell lines, whereas Cav3.2 was prominent 
in the cell lines displaying a faster proliferation rate, and Cav3.3 was expressed in a smaller range of 
highly proliferative cell lines. In a follow-up histochemical study we reported that Cav3.1 and Cav3.2 
immunostainings were augmented in malignant melanoma and nevi, compared to normal skin, and 
showed a positive association with Breslow thickness [16]. Furthermore, the Histoscore for Cav3.2 
was higher in metastatic vs. primary melanomas, and showed a three-way correlation with 
proliferative (Ki-67) and hypoxia (Glut-1) markers. Chronic or acute hypoxia, known to upregulate 
Cav3.2 channels through the activation of HIF-1 [10][11] and HIF-2 [9], are critical regulators of 
stemness in cancer cells [17]. Moreover, a role for Cav3.2 in stemness maintenance was revealed in 
glioma stem cells [18][19]. Our study also indicated that melanoma biopsies bearing the BRAFV600E 
mutation displayed a higher immunolabeling for Cav3.1, which positively correlated with that of 
microtubule-associated protein light chain 3 (LC3), an autophagosome marker, and with loss of tumor 
suppressor PTEN [16]. It was previously known that BRAFV600E-driven melanomas exhibit enhanced 
(macro)autophagy [20], and that autophagy inhibition improves the sensitivity of BRAFV600E brain 
cancers to BRAF inhibitor vemurafenib [21]. The trilateral links between Cav3.1, BRAFV600E mutation 
and autophagy were confirmed by Maiques and colleagues, who described a facilitating role of 
autophagy in melanoma invasivity [22]. In this work, it was also shown that Cav3.1 and Cav3.3 channel 
transcripts are expressed at higher levels in BRAFV600E compared with NRASQ61H/K/L/R mutant cell lines.  
The reported associations of TTCCs with proliferation or autophagy markers, and with oncogenic 
BRAF/NRAS/PTEN mutations are indicators of bad prognosis by themselves. This was directly 
demonstrated in patient cohorts by in silico genomic analysis of The Cancer Genome Atlas (TCGA) 
database, which revealed that the upregulation of Cav3.1 or Cav3.2 isoforms were strongly associated 
to poor outcomes in Kaplan-Meier estimates [16]. Likewise, a TGCA analysis performed by Granados 
and colleagues demonstrated that melanoma patients with tumors displaying a higher expression of 
Cav3.2 have a worse survival, although Cav3.1 was neglected from this study [23]. Table 1 summarizes 
the reported relationships between the expression of TTCCs isoforms, associations with prognosis 
markers and effects of specific gene silencing. 
  
T-type channels as drivers of resistance to MAPK inhibitors  
The prevalence of oncogenic BRAF and RAS mutations implies the hyperactivation of pathways that 
favor proliferation, survival and creation of an optimal microenvironment for melanoma tumor 
growth [4]. Although many patients with BRAF- or NRAS-mutant melanoma benefit initially from 
BRAF- or MEK- targeted therapies, resistance to the treatment or secondary malignacies develop 
almost inexorably. Among the known mechanisms for recurrence there is the reactivation of the 
MAPK pathway as a result of adaptive signaling through upstream receptor tyrosine kinases, or due 
to the development of secondary mutations in components of the pathway [24]. In addition, 
compensatory activation of PI3K [25], the unfolded protein response (UPR) [26] and autophagy 
[26][27] have all been shown to promote resistance to MAPK inhibitors.  
The dependency of BRAF- and RAS-mutant cells on autophagy for survival within the tumor 
microenvironment, and their increased susceptibility to autophagy inhibitors are well-documented 
[21][28]. Furthermore, overexpression of oncogenic BRAF has shown to trigger autophagy and induce 
a senescence-like phenotype in melanoma cells [20]. The mechanisms for induction of autophagy in 
these cells, overwhelming the constitutive activation of anti-autophagic mammalian target of 
rapamycin C1 (mTORC1) by MAPK and PI3K-Akt pathways, have not been completely elucidated. In 
bladder cancer cells activation of the MAPK pathway can promote autophagy by ERK1/2-mediated 
inhibition of Beclin-1 negative regulators, thus facilitating the formation of the class III PI3K complex 
[29]. In addition, ERK1/2-dependent phosphorylation of Gα-Interacting Protein (GaIP) has been 
shown to induce autophagic sequestration in colon cancer cells [30] (Figure 1).  
The above-reported upregulation of TTCCs in BRAFV600E mutant cells adds a piece to the puzzle of 
melanoma progression which gets even more complicated upon analysis of tumor resistance to 
MAPK inhibitors. Following the trail of research performed in glioblastoma (GBM), which unveiled a 
positive association between the expression of Cav3.1 and chemotherapeutic resistance to alkylating 
agent temozolomide [31], Barceló and colleagues have recently reported the increased expression of 
Cav3.1 channel transcripts in vemurafenib-resistant BRAFV600E-mutant, compared to vemurafenib-
sensitive BRAFV600E melanoma cells [27]. In addition, consultation of the Gene Expression Omnibus 
repository database revealed higher levels of Cav3.1 transcripts in melanomas from patients after 
treatment with BRAF inhibitors. Like temozolomide-resistant GBM cells, vemurafenib-resistant 
melanoma cells displayed increased autophagosomal-associated LC3-phosphatidylethanolamine 
conjugate (LC3-II) levels, indicating enhanced basal autophagy with respect to their vemurafenib-
sensitive counterparts. Moreover, the authors found that PTEN-deficient vemurafenib-resistant cells 
expressed the highest levels of Cav3.1 mRNA. The circle of evidence was closed by PTEN gene 
knockdown in PTEN-competent cells, resulting in augmented expression of Cav3.1 and conversely, 
overexpression of PTEN in PTEN-deficient cells resulting in reduced Cav3.1 transcript levels. However, 
the analysis of Cav3.2 transcripts in these conditions was not performed.  
Another recent article reported that TTCC expression was upregulated in partially reprogrammed (by 
transduction of genes encoding pluripotency factors) BRAF and NRAS mutant-melanoma cells, 
acquiring features of stemness, slower proliferation and enhanced invasivity [23]. De-differentiated 
cells increased the expression of transcripts for Cav3.2 (particularly the NRAS mutants), in agreement 
with its known role in stemness, although the analysis of Cav3.1 transcripts was omitted. However 
and in contrast to the above-mentioned work, when melanoma cells were challenged with 
vemurafenib, both Cav3.1 and Cav3.2 isoforms were upregulated. Crucially, de-differentiated BRAF or 
NRAS mutant cells also became resistant to MAPK inhibitors such as vemurafenib (targeting BRAF) 
and trametinib (targeting downstream MEK1/2). These results are summarized in Table 2.  
 
Targeting of T-type channels in vitro and in vivo  
Many of the existing compounds with a proven ability to block TTCCs, originally developed against 
cardiovascular disorders or neurological conditions, display antagonism against different types of 
Ca2+, Na+, and K+ channels and metabotropic receptors [32][33]. Tetralol-derivative mibefradil and 
diphenylbutylpiperidine-derivative pimozide are amongst the most widely used pharmacological 
blockers of TTCCs in cancer research, both in vitro and in preclinical models. These compounds are 
cytotoxic at about 5 to 10-fold supramaximal concentrations, suggesting that at least part of these 
effects are off-target [34]. In our pioneering works we used both compounds at 10 M because we 
estimated half maximal effective concentrations (EC50) on cell viability between 5-8 M, depending 
on melanoma cell lines [47]. We found that exposure to mibefradil or pimozide at 10 M exerted a 
dual effect by inducing cell cycle arrest and caspase-dependent apoptosis in a wide range of 
melanoma cells [35]. Apoptosis was preceded by endoplasmic reticulum stress and activation of the 
UPR. In addition, concomitant increased levels of LC3-II and of p62, a protein that acts as cargo 
receptor and becomes an autophagy substrate [36], as well as the accumulation of polyubiquitin 
aggregates, indicated a defective autophagy. Gene knockdown of TTCCs by siRNA transfection 
partially mimicked the effects of pharmacological blockers on UPR and autophagy markers, and 
induced apoptotic cell death.  
Because reportedly vemurafenib-resistant BRAFV600E cells display increased expression of Cav3.1, it 
could be expected that their viability is more dependent on these channels and thus more sensitive 
to TTCC blockers, compared to non-adapted BRAFV600E cells. However, Barceló and colleagues did not 
observe significant differences in the EC50 of mibefradil on both cell types. In addition, the PTEN status 
did not affect the sensitivity of melanoma cells to mibefradil, in spite of decreasing (when 
overexpressed) or decreasing (when knocked down) Cav3.1 transcript levels manifold [27]. In 
contrast, Granados and colleagues described enhanced sensitivity to mibefradil or its derivative NNC-
55-0396 (but not to diphenylpiperazine-derivative lomerizine) for de-differentiated BRAFV600E and 
RAS mutant melanoma cell lines, irrespective of their PTEN status (Table 2). Furthermore, mibefradil, 
NNC-55-0396 or knockdown of Cav3.2 induced apoptosis, differentiation and restored the sensitivity 
of de-differentiated BRAFV600E vemurafenib-resistant cells to MAPK inhibition.  
The effect of mibefradil on vemurafenib-resistant melanoma was further analyzed in vivo. Barceló 
and colleagues orally treated immunodeficient SCID xenografted mice with vemurafenib, mibefradil 
or both for 2 weeks, on a daily basis [27]. Co-administration of mibefradil delayed the growth of 
vemurafenib-sensitive and resistant cell line-derived xenografts, when compared to either untreated 
mice or mice treated with only vemurafenib. Similarly, Granados and colleagues orally administered 
vemurafenib and/or mibefradil to immunodeficient NSG xenografted mice: both drugs synergized in 
two sequential applications for up to 20 days, to slow tumor growth and extend the survival of 
xenografted mice in Kaplan-Meier estimates [23].  
The role of TTCCs in melanoma motility and invasivity has also been under scrutiny. Both parameters 
were reduced by mibefradil, as well as by the macroautophagy inhibitor chloroquine, specifically in 
BRAFV600E but not in NRASQ61L melanoma cells [22]. In addition, gene knockdown of Autophagy-
Related Gene 5 (Atg5, key for phagophore extension) reduced migration of both cell lines in wound-
healing assays, and silencing of Cav3.1 or Cav3.2 (the latter more strongly) reduced the invasion 
capacity of BRAFV600E mutants in transwell assays. The expression of Snail1, a zinc-finger transcription 
factor involved in migration, paralleled the autophagic status and was reduced by both TTCC 
pharmacological blockers and Cav3.1/Cav3.2 gene knockdown. These results contribute to conflicting 
evidence about the involvement of autophagy in metastasis. In early stages, autophagy may oppose 
metastasis by limiting necrosis and inflammation. However, when metastasis is initiated, autophagy 
may promote detachment from the extracellular matrix (ECM) and survival to anoikis [37][38][39]. 
Nonetheless, the influence of autophagy on the Epithelial-Mesenchymal Transition (EMT), the 
process by which epithelial cancer cells lose adhesion to the ECM, de-differentiate and migrate to a 
distant location, can be double-sided. For example, in GBM cells autophagy inhibition by gene 
silencing of Beclin-1, Atg5, or Atg7 increased the migration and invasion capacities [40]. These 
disparate conclusions indicate that the links between autophagy and EMT may occur at different 
levels and vary according to cancer types and underlying genetics. 
 
Concluding remarks 
Altogether, data obtained in the last decade suggest that TTCC pharmacological blockers might be 
used to inhibit signaling pathways used in melanoma progression and invasion. Moreover, two recent 
reports indicate that TTCC targeting might prevent, overcome or delay melanoma resistance to MAPK 
inhibitors. Of note, the relationship between BRAFV600E and TTCCs appears to be bidirectional: (1) the 
expression of TTCCs is increased in BRAFV600E mutant cells, and further increased in mutant cells 
resistant to MAPK inhibitors. Hence, the MAPK pathway controls the transcription of genes encoding 
TTCCs. (2) Gene silencing or pharmacological block of TTCCs restore the sensitivity to MAPK 
inhibitors. Hence, TTCCs seem to activate the MAPK pathway downstream of BRAF or, at least, to 
make melanoma cells dependent on this pathway (Figure 1). The molecular mechanisms behind this 
two-way positive feedback are unknown at present.  
In addition, the expression of Cav3.1 was found to correlate with loss of PTEN. PTEN acts as a tumor 
suppressor by inhibiting the PI3K-Akt pathway as well as other PI3K-independent actions [41]. PTEN 
loss-of-function occurs in 30-60% of melanomas, and has been suggested to cooperate with BRAFV600E 
mutations in the genesis of metastatic melanoma [42]. Importantly, both preclinical and clinical 
studies have shown that PTEN deficiency impairs BRAF-targeted treatments [41][43]. Thus, 
combinatorial targeting of MAPK and PI3K-Akt pathways is a prospective approach to overcome 
resistance and cross-resistance mechanisms [44]. Although no direct interactions have been reported 
between TTCCs and components of the PI3K-Akt pathway, TTCC pharmacological block or gene 
silencing are known to dephosphorylate prosurvival Akt in GBM [45][19] and ovarian [46] cancers. 
Altogether, the activity of TTCCs would allow to circumvent BRAF inhibition by dual downstream 
activation of the MAPK and the mTORC2-Akt pathways. In turn, activation of these pathways would 
feed back on TTCC expression (Figure 1). The positive correlation between the expression of Cav3.1 
and autophagy, and the reported effects of TTCC pharmacological block/silencing on UPR and 
autophagy, are also part of the jigsaw for adaptation of melanoma cells to MAPK inhibitors. 
In conclusion, TTCCs are valuable prognostic markers and promising molecular targets in melanoma. 
However, further research is required to elucidate the coupling of TTCC-mediated Ca2+ entry with 
adaptive signaling pathways and cellular processes used in melanoma progression, invasion and 
chemoresistance, in which macroautophagy appears to play a leading role. In addition, the 
pharmacological targeting of TTCCs needs to be further outlined. The different TTCC isoforms 
perform different functions in cancer physiology, and currently available compounds are not only 
unable to distinguish between them, but at cytotoxic concentrations exert off-target effects which 
need to be carefully dissected. On that account, the delivery of efficacious therapies targeting TTCCs 
in melanoma is likely to parallel the timeline for development of highly selective inhibitors.  
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Figure Legends: 
Figure 1: 
Double-sided interaction of TTCCs with MAPK and mTORC2-Akt pathways define two feedback loops 
(red arrows). The expression of TTCCs is increased in cells with overactive MAPK (BRAFV600E and RAS 
mutants) and PI3K/mTORC2-Akt (RAS mutants/PTEN mutants) pathways. Conversely, block/gene 
silencing of TTCCs restore the sensitivity of resistant cells to MAPK inhibitors, and inhibit the mTORC2 
pathway. Both these pathways are known to favor cell growth at the transcriptional level and inhibit 
autophagy initiation by mTORC1 activation. Contrarywise, ERK1/2 may induce macroautophagy by 
facilitating Beclin-1-mediated nucleation of the phagophore and by GaIP-mediated autophagic 
sequestration. Arrow tips indicate whether the modulation is positive (pointed) or negative (round). 
RTK stands for Receptor Tyrosine Kinase. 
 
 
 
 
 
  
 
Table 1: Correlation between TTCCs expression and prognostic markers, and effects of gene 
silencing in melanoma cells 
N.A.: not addressed 
 
TTCCs 
isoform 
Positive 
associations Prognostic Effects of  gene silencing References 
Cav3.1 
 
Breslow 
thickness 
Autophagy 
(LC3-II)  
EMT (Snail1)  
BRAFV600E  
PTEN deletion  
 
Negative 
Cell cycle arrest  
Unfolded protein response  
Defective autophagy  
Apoptosis 
Reduced migration/invasion 
Increased sensitivity to vemurafenib  
 
[15, 16, 27, 35] 
 
Cav3.2 
 
Breslow 
thickness 
Metastasis 
Stemness 
(Sox2, SSEA1) 
Proliferation 
(Ki-67) 
Hypoxia (Glut-
1) 
 
Negative 
 
Cell cycle arrest  
Unfolded protein response  
Defective autophagy  
Apoptosis  
Differentiation 
Increased sensitivity to  vemurafenib 
and trametinib 
 
[15, 16, 23, 27, 
35]  
Cav3.3 
 
Metastasis 
BRAFV600E  
 
 
N.A. N.A. [15, 27]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Mutational status of melanoma cells relative to cell phenotype, TTCC expression and 
sensitivity to TTCC inhibition. N.A.: not addressed 
Mutational status 
Correlation 
with other 
markers 
Phenotyp
e 
Relative 
expression of 
TTCC isoforms   
Sensitivity to  
pharmacological 
block or gene 
silencing  
Referen
ces 
BRAFV600E 
(vs NRAS-mut)  
LC3-II  
Snail1  
PTEN-
deficiency 
Autoph
agy 
Invasivit
y 

Cav3.1  
≈ Cav3.2 
Cav3.3  
 
Similar [16, 22, 27] 
Vem.-resistant  
BRAFV600E 
(vs sensitive) 
 
N.A. 
 
Autoph
agy 
Cav3.1  
(other isoforms 
N.A.) 
Similar [27] 
Vem./ Tram.-resistant 
BRAFV600E  
(vs sensitive) 
N.A. N.A. 
Cav3.1 
Cav3.2 
(Cav3.3 N.A.) 
Increased [23] 
Vem./ Tram.-resistant 
NRAS-mut (vs 
sensitive) 
 
N.A. 
 
N.A. 
Cav3.1 
Cav3.2 
(Cav3.3 N.A.) 
Increased [23] 
PTEN deficiency 
 
LC3-II  
BRAF-mut 
 
Autoph
agy 

Cav3.1  
(other isoforms 
N.A.) 
 
Similar 
 
 [16, 22, 
27] 
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